Print

Arakis Ltd. Commences Phase IIb Trial Ror RA Drug 
10/19/2005 5:09:12 PM

Arakis (Sosei) has commenced a Phase IIb dose-ranging study of AD 452, a novel, small-molecule, disease-modifying antirheumatic drug, designed to reduce joint inflammation and destruction, pain and preserve mobility.
//-->